These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells. Leclerc JM; Momparler RL Cancer Treat Rep; 1984 Sep; 68(9):1143-8. PubMed ID: 6592037 [TBL] [Abstract][Full Text] [Related]
23. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system. Raymakers RA; Slocum HK; Minderman H; Malmberg M; Rustum YM Exp Hematol; 1993 May; 21(5):602-7. PubMed ID: 8513859 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. Kishi S; Goto N; Nakamura T; Ueda T Cancer Res; 1999 Jun; 59(11):2629-34. PubMed ID: 10363985 [TBL] [Abstract][Full Text] [Related]
25. The chemokine CCL21 protects normal marrow progenitors from Ara-C cytotoxicity. Hromas R; Cooper S; Broxmeyer HE Cancer Chemother Pharmacol; 2002 Aug; 50(2):163-6. PubMed ID: 12172984 [TBL] [Abstract][Full Text] [Related]
26. [The effects of histamine H2 receptor agonist, antagonist and antineoplastic agent on the in vitro growth of PB CFU-GM from normal individuals and HL-60 leukemia cells]. He Q; Xu YH Yao Xue Xue Bao; 1996; 31(5):340-5. PubMed ID: 9275711 [TBL] [Abstract][Full Text] [Related]
27. Prevention of hematotoxic side effects of cytostatic drugs in mice by a synthetic hemoregulatory peptide. Paukovits WR; Guigon M; Binder KA; Hergl A; Laerum OD; Schulte-Hermann R Cancer Res; 1990 Jan; 50(2):328-32. PubMed ID: 2295072 [TBL] [Abstract][Full Text] [Related]
28. Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells. Minford J; Kerrigan D; Nichols M; Shackney S; Zwelling LA Cancer Res; 1984 Dec; 44(12 Pt 1):5583-93. PubMed ID: 6208999 [TBL] [Abstract][Full Text] [Related]
29. Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs. Park CH; Wiernik PH; Morrison FS; Amare M; Van Sloten KV; Maloney TR Cancer Res; 1983 May; 43(5):2346-9. PubMed ID: 6572563 [TBL] [Abstract][Full Text] [Related]
30. Cytosine arabinoside as a suicide agent for human colony forming cells. Dresch C; El Kebir N; Metral J; Karsdorf A Exp Hematol; 1983 Mar; 11(3):187-92. PubMed ID: 6832245 [TBL] [Abstract][Full Text] [Related]
31. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations. Kim K; Blechman WJ; Riddle VG; Pardee AB Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006 [TBL] [Abstract][Full Text] [Related]
32. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia. Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985 [TBL] [Abstract][Full Text] [Related]
33. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity. Vadi H; Drewinko B Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232 [TBL] [Abstract][Full Text] [Related]
34. Potentiation of cytotoxicity of 1-beta-D-arabinofuranosylcytosine for K562 human leukemic cells by cadeguomycin. Suzuki H; Kim SH; Tanara M; Okazaki K; Okabe T; Wu RT; Tanaka N Cancer Res; 1987 Feb; 47(3):713-7. PubMed ID: 3467840 [TBL] [Abstract][Full Text] [Related]
35. Effects of S-phase-specific agents on granulocyte-macrophage and erythroid progenitor cells obtained from normal individuals and from patients with chronic myelogenous leukemia. Kubota K; Preisler HD; Costanzo C Cancer Res; 1983 Aug; 43(8):3927-31. PubMed ID: 6574819 [TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of murine stem cell factor in combination with a variety of cytokines on the expansion of murine hematopoietic progenitor cells in short-term suspension cultures. Han M Hokkaido Igaku Zasshi; 1992 Sep; 67(5):674-83. PubMed ID: 1385289 [TBL] [Abstract][Full Text] [Related]
37. Schedule-dependent synergistic cytotoxicity of arabinofuranosylcytosine with adriamycin or 3,6-bis(5-chloro-2-piperidinyl)-2,5-piperazinedione in cultured cells. Rao PN; Mahagaokar S; Freireich EJ; Loo TL; Gottlieb JA Cancer Res; 1975 Nov; 35(11 Pt 1):2996-3000. PubMed ID: 1182694 [TBL] [Abstract][Full Text] [Related]
38. Sensitivity of human granulopoiesis in vitro to adriamycin before and after exposure in vivo. Lohrmann HP; Schreml W Cancer Res; 1979 Feb; 39(2 Pt 1):527-30. PubMed ID: 761226 [TBL] [Abstract][Full Text] [Related]
39. Endotoxin-induced size change in bone marrow progenitors of granulocytes and macrophages. Metcalf D; Wilson JW J Cell Physiol; 1976 Nov; 89(3):381-91. PubMed ID: 977658 [TBL] [Abstract][Full Text] [Related]
40. Influence of dose and duration of exposure on the cytotoxic effect of cytarabine toward human hematopoietic clonogenic cells. Muus P; Haanen C; Raijmakers R; de Witte T; Salden M; Wessels J Semin Oncol; 1987 Jun; 14(2 Suppl 1):238-44. PubMed ID: 3473679 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]